A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 1,023 (planned)
- Started
- Jan 19, 2026
- Main results expected
- Oct 29, 2031
- Fully finished
- Oct 29, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1 Safety Run-in: Number of Participants Who Experience One or More Adverse Events (AEs)
Measured over: Up to approximately 69 months
Part 1 Safety Run-in: Number of Participants Who Discontinue Study Treatment Due to an AE
Measured over: Up to approximately 66 months
Part 2 Maintenance Treatment: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 48 months
Part 2 Maintenance Treatment: Overall Survival (OS)
Measured over: Up to approximately 60 months
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- 2026-11-06 15:29 UTC · paperwork · other
old: null
new: null
details: {"sections":["eligibilityModule","statusModule"]}
Trial ID NCT07216703 · record last updated 2026-11-06 · checked 2026-11-09 15:36 UTC